The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.
about
Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathiesClinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance RegistryJuvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damageHigh prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort.Autoimmune neuromuscular disorders in childhoodGenetic association study of NF-κB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy.The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patientsThe clinical phenotypes of the juvenile idiopathic inflammatory myopathies.Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies.Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study.Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience.A systematic review of juvenile-onset clinically amyopathic dermatomyositis.Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?Cardiovascular risk in pediatric-onset rheumatological diseases.The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomesPredictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.Clinical characteristics and outcomes of juvenile and adult dermatomyositisOverexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositisComparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression.Feeding and Swallowing Disorders in Pediatric Neuromuscular Diseases: An Overview.Consensus-based recommendations for the management of juvenile dermatomyositis.Onset of juvenile dermatomyositis following varicella infection in a 12-month-old child: a case report.In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity.Clinical features and disease course of patients with juvenile dermatomyositis.Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.Innovative research methods for studying treatments for rare diseases: methodological review.Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies.Role of MRI in diagnosis and management of idiopathic inflammatory myopathies.A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset.Serological subsets of juvenile idiopathic inflammatory myopathies--an update.Treatment of Juvenile Dermatomyositis: An Update.Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children.Whole-body MRI: non-oncological applications in paediatrics.Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
P2860
Q26863125-DF9D0AE4-1C62-47E0-A1CB-CD3C3BF77797Q33834285-D7144563-5E90-47AE-8EE5-4C7A376DE2DAQ35009335-04BE703B-F70E-488B-A191-7229D69EE68BQ35125063-0D1F2994-0CBE-4CDF-9B3B-6B6EBAED1C43Q35225827-506A3D65-8734-40BF-9D3B-DF810FCB0F2AQ35512273-88B96D87-C1E9-4859-B448-996919F84DC4Q35890979-66456328-1370-468A-9037-668C16DC8988Q36056490-1FBCABEA-5697-4799-AD4E-ABB6F86C5072Q36086954-2428A02B-6BDE-4689-9AEA-6AD9B6B2DC9FQ36283423-859D28AC-AC35-4D8F-B8EA-5C9A80A80EA2Q36498667-86F8F31C-025A-4373-AE17-1C3A12D1CECAQ36689941-45001E49-8FE7-4DE1-8239-BFD8EC91B818Q36862644-072F9F65-E55C-4D16-AAB8-EF3009AEA48DQ36903076-2ADAB860-89D5-491C-85D2-6C36B7E64E42Q36903089-4A12A5B3-36B9-405D-A0C0-0BEE48FEA417Q37022721-C0DC5B85-BAB8-4A69-84FF-DA6D8F89E35DQ37172923-97AC5113-9B35-4911-BF70-9A2063D7531BQ37240498-7D48E1E3-AFAD-41FB-992F-56F1CB365465Q37284770-290197E5-6A99-4CB3-BF33-15E4CA1D7A47Q37316480-B875EA2C-C68C-48E0-948D-6F94BF4D2F74Q37316551-80DA2640-791F-4FDF-B6F9-EAC90A662D98Q37368405-74E65BF9-8A26-427C-BCE6-08206B8923D3Q37427265-7D9D76BD-8ECD-45B9-86A5-ED8A00447342Q37480302-DDF2C529-DB40-4681-A21E-6C9D6E3A1740Q37589746-060B2B47-651D-48A7-949D-F41D73020239Q37617000-5B973981-7454-4D06-8209-B04534D60996Q37623967-43293BB5-F1D8-41A2-8126-DBDB1E2631FCQ38123764-8DB3F5BE-A9D8-4250-85E6-574788796ABEQ38155955-B10DAFB0-4A65-47DC-9E0D-C25B4898F527Q38216182-E8F78C2C-4548-46A3-A7CB-3DA429808402Q38271185-571FE58C-B4E1-4DFA-B3FB-E8B2034B37DFQ38281749-DC7D20CE-C4B1-4258-A565-3AC9306397C9Q38589395-1CEB750A-BB11-4CDA-8533-352C79F13B91Q38613322-2ED4D391-E77F-4EF5-A51D-5F2392C98C93Q38616245-EF6CE35F-A996-438C-88F8-26D6A51B3141Q38664251-B2A181E8-5C14-4FA2-8384-D6B276907E70Q38678257-132D21C1-2075-4EF2-A1CB-A2279A0D4C3CQ38690044-3601E6D8-8591-4C53-8E55-C4CAEF1A877EQ38739720-817F5080-1AB6-47AF-AA10-CA2C5649B044Q38836830-5E8B3521-73BA-4A44-A14E-4E20AFEC04E4
P2860
The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The Juvenile Dermatomyositis N ...... cruited within the first 5 yr.
@ast
The Juvenile Dermatomyositis N ...... cruited within the first 5 yr.
@en
type
label
The Juvenile Dermatomyositis N ...... cruited within the first 5 yr.
@ast
The Juvenile Dermatomyositis N ...... cruited within the first 5 yr.
@en
prefLabel
The Juvenile Dermatomyositis N ...... cruited within the first 5 yr.
@ast
The Juvenile Dermatomyositis N ...... cruited within the first 5 yr.
@en
P2093
P356
P1433
P1476
The Juvenile Dermatomyositis N ...... cruited within the first 5 yr.
@en
P2093
A D Juggins
C A Pilkington
J E Davidson
Juvenile Dermatomyositis Research Group
K J Murray
L J McCann
L R Wedderburn
S M Maillard
P304
P356
10.1093/RHEUMATOLOGY/KEL099
P577
2006-03-27T00:00:00Z